Page 67 - HPV e 100 domande
P. 67

AGMGIAORGNGAIMOE2N0T1O8:

          Olsson SE, Kjaer SK, Sigurdsson K et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine
             efficacy cervical and anogenital disease in subjects with serological evidence of prior vac-
             cine type HPV infection. Hum Vaccin 2009;5(10):696-704.

          Paavonen J, Naud P, Salmeròn J et al. Efficacy of Human papillomavirus (HPV)-16/18
             ASO4-adjuvanted vaccine against cervical infection and precancer caused by oncogenic
             HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
             Lancet 2009;374:301-14.

          Rapporto sulla sorveglianza postmarketing dei vaccini in Italia 2016. http://www.aifa.gov.it/
             sites/default/files/Rapporto_Vaccini_2016.pdf [ultimo accesso 1 marzo 2018].

          Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human
             papilloma virus vaccines. Nature Rev Microbiol 2012;10:681-92.

          Schwarz TF, Galaj A, Spaczynski M et al. Ten-year immune persistence and safety of the HPV-
             16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age. Cancer Med
             2017;6(11):2723-31. doi: 10.1002/cam4.1155. Epub 2017 Oct 5.

          Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review.
             Expert Opinion on Drug Safety 2015; 14(5):697-712.

          Van Damme P, Meijer CJ, Kieninger D, et al. A Phase IIIclinical study to compare the im-
             munogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine
             2016;34(35):4205-12.

          Vesikari T, Brodszki N, Van Damme P, et al. A randomized,double-blind, Phase III study of the
             immunogenicity and safety of a 9-valent human papillomavirus l1 virus-like particle vaccine
             (V503) versus gardasil® in 9–15-year-old girls. Pediatr Infect Dis J 2015;34(9):992-98.

          WHO. Human papillomavirus vaccines: WHO position paper, 2017. WER 2017;9(19):241-68.
             http://apps.who.int/iris/bitstream [ultimo accesso 1 marzo 2018].

          WHO. Safety update of HPV vaccines- World Health Organization. Meeting of the global ad-
             visory committee on vaccine safety, 7-8 June 2017. WER 2017;92(28): 393-404. http://
             www.who.int/vaccine_safety/committee/topics/hpv/June_2017/en [ultimo accesso 1 mar-
             zo 2018].

          Zhai L, Tumban E. Gardasil-9: A global survey of projected efficacy. Antiviral Res 2016;130:101-
             109. doi: 10.1016/j.antiviral.2016.03.016. Epub 2016 Apr 1.

          NOTE

Le 100 DOMANDE sull’HPV         65
Informazioni per gli operatori
   62   63   64   65   66   67   68   69   70